Mesalamine Prolonged Release Tablet About
Find unassailable relief with UCOCARE Mesalamine Prolonged Release Tablets-designed to deliver astounding support in managing ulcerative colitis. Each white, oblong tablet contains a redoubtable 1.2 g of mesalamine, precisely formulated for gradual, targeted release in the colon. Securely packaged in Alu-Alu blisters within a sturdy cardboard box, you get 10 tablets per pack, perfect for adult patients seeking dependable anti-inflammatory action. Featured under strict export and manufacturing quality from India, UCOCARE offers a trusted solution for those who demand efficacy and safety in bowel disease treatment.
Targeted Relief for Ulcerative Colitis
Mesalamine Prolonged Release Tablets are specially indicated for patients battling ulcerative colitis. Their general use extends as an anti-inflammatory treatment for various bowel diseases, designed for adults. The unique advantage lies in the prolonged release, ensuring sustained therapeutic action directly in the colon. With its white, oblong shape and precise 1.2 g dosage per tablet, special features include convenient aluminum-aluminum blister packaging and a user-friendly cardboard box for enhanced safety and product integrity.
Sample Policy & Export Highlights
Our Mesalamine Prolonged Release Tablet samples are dispatched promptly upon official purchase order confirmation, supporting valued evaluations and market trials. UCOCARE boasts substantial supply ability to meet both domestic and global demand. Main export markets include Asia, Africa, and the Middle East, reflecting the product's competitive market value and trusted efficacy. As a reliable exporter, manufacturer, service provider, and supplier from India, we ensure consistent availability and professional service for our clients.
FAQ's of Mesalamine Prolonged Release Tablet:
Q: How should Mesalamine Prolonged Release Tablets be used for ulcerative colitis?
A: These tablets are intended for adults diagnosed with ulcerative colitis. The typical dosage is 1.2 g, taken as directed by the prescribing physician. Always follow your doctor's specific guidelines.
Q: What makes the prolonged release feature of UCOCARE Mesalamine tablets beneficial?
A: The prolonged release formulation ensures continuous, targeted delivery of mesalamine in the colon, optimizing its anti-inflammatory effect and potentially improving treatment outcomes for patients.
Q: When should I expect to notice improvements after starting treatment?
A: Response times can vary, but many patients begin to experience improvements in their symptoms after consistent usage. Persistent or adverse reactions should always be reported to a healthcare provider.
Q: Where is UCOCARE Mesalamine Prolonged Release Tablet manufactured and supplied from?
A: This medication is manufactured, exported, and supplied from India, meeting rigorous quality standards suitable for domestic and international markets.
Q: What is the process for ordering and receiving samples for evaluation?
A: Samples are promptly dispatched after confirmation of your purchase order. Please contact our sales team to initiate the process and discuss your market's requirements.